Peptide drugs encompass a variety of therapeutic options, including peptide vaccines, antitumor peptides, antiviral peptides, peptides targeting specific pathogens, cytokine-mimicking antibacterial peptides, and peptides used in other small molecule pharmaceutical applications. Compared to traditional organic small-molecule drugs, peptide-based drugs offer several advantages: they tend to have potent pharmacological effects, require lower dosages, exhibit fewer side effects, and show more significant therapeutic outcomes. However, a notable challenge is their relatively short half-life, as they are often rapidly metabolized or degraded in the body.
Peptides for Anti-Tumor Therapy
Tumor cell formation is the result of a range of factors, ultimately leading to the dysregulation of oncogene expression. The enzymes involved in the formation of various types of malignant tumors differ in their activity and control. By targeting specific enzymes or signaling pathways related to tumor metastasis, it is possible to prevent tumor spread by inhibiting the active centers required for metastasis. Current research in genomics and the molecular control mechanisms of malignant tumors has shifted focus toward identifying active peptides that can specifically target these oncogenic pathways. This area has become a critical avenue for the development of novel anti-cancer drugs.
Antiviral Peptide Therapies
Pathogens, such as viruses, infect host cells by binding to specific receptors on the cell surface and utilizing the host's proteases for protein processing and nucleic acid replication. Therefore, peptides that can bind to human cell receptors or inhibit pathogen-related proteases hold potential as antiviral agents. By selecting peptides from specialized libraries that target these interactions, researchers can develop effective antiviral treatments that interfere with the pathogen's ability to infect and replicate within human cells.
